BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 32520974)

  • 1. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
    Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
    PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance.
    Okada T; Mizukami Y; Ono Y; Sato H; Hayashi A; Kawabata H; Koizumi K; Masuda S; Teshima S; Takahashi K; Katanuma A; Omori Y; Iwano H; Yamada M; Yokochi T; Asahara S; Kawakubo K; Kuwatani M; Sakamoto N; Enomoto K; Goto T; Sasajima J; Fujiya M; Ueda J; Matsumoto S; Taniue K; Sugitani A; Karasaki H; Okumura T
    J Gastroenterol; 2020 Dec; 55(12):1183-1193. PubMed ID: 32939577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
    Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
    J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
    Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
    Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
    Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
    Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
    Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
    Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer.
    Liu X; Liu L; Ji Y; Li C; Wei T; Yang X; Zhang Y; Cai X; Gao Y; Xu W; Rao S; Jin D; Lou W; Qiu Z; Wang X
    EBioMedicine; 2019 Mar; 41():345-356. PubMed ID: 30857943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision oncology: Artificial intelligence, circulating cell-free DNA, and the minimally invasive detection of pancreatic cancer-A pilot study.
    Bahado-Singh RO; Turkoglu O; Aydas B; Vishweswaraiah S
    Cancer Med; 2023 Oct; 12(19):19644-19655. PubMed ID: 37787018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma.
    Henriksen SD; Madsen PH; Larsen AC; Johansen MB; Drewes AM; Pedersen IS; Krarup H; Thorlacius-Ussing O
    Clin Epigenetics; 2016; 8():117. PubMed ID: 27891190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers' Discovery.
    Brancaccio M; Natale F; Falco G; Angrisano T
    Genes (Basel); 2019 Dec; 11(1):. PubMed ID: 31877923
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Takase Y; Naito Y; Kawahara A; Okabe Y; Sadashima E; Abe H; Akiba J
    Anticancer Res; 2023 Jun; 43(6):2683-2690. PubMed ID: 37247923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
    Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood.
    Eissa MAL; Lerner L; Abdelfatah E; Shankar N; Canner JK; Hasan NM; Yaghoobi V; Huang B; Kerner Z; Takaesu F; Wolfgang C; Kwak R; Ruiz M; Tam M; Pisanic TR; Iacobuzio-Donahue CA; Hruban RH; He J; Wang TH; Wood LD; Sharma A; Ahuja N
    Clin Epigenetics; 2019 Apr; 11(1):59. PubMed ID: 30953539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.